## Michel Burnier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7795522/publications.pdf

Version: 2024-02-01

287 papers 29,757 citations

53 h-index 163 g-index

303 all docs 303 does citations

times ranked

303

35243 citing authors

#	Article	IF	CITATIONS
1	Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. Nephrology Dialysis Transplantation, 2023, 38, 10-25.	0.7	30
2	Partnership between patients and interprofessional healthcare providers along the multifaceted journey to medication adherence. British Journal of Clinical Pharmacology, 2023, 89, 1992-1995.	2.4	2
3	Cortical perfusion as assessed with contrast-enhanced ultrasound is lower in patients with chronic kidney disease than in healthy subjects but increases under low salt conditions. Nephrology Dialysis Transplantation, 2022, 37, 705-712.	0.7	8
4	Assessment of hypertension in kidney transplantation by ambulatory blood pressure monitoring: a systematic review and meta-analysis. CKJ: Clinical Kidney Journal, 2022, 15, 31-42.	2.9	14
5	Nutritional management of sodium, chloride, and water in kidney disease and kidney failure. , 2022, , 313-328.		О
6	Improving the Management of Hypertension by Tackling Awareness, Adherence, and Clinical Inertia: A Symposium Report. American Journal of Cardiovascular Drugs, 2022, 22, 251-261.	2.2	10
7	Nonadherence in Hypertension: How to Develop and Implement Chemical Adherence Testing. Hypertension, 2022, 79, 12-23.	2.7	51
8	Prevalence and Factors Associated with Opioid Prescription in Swiss Chronic Hemodialysis Patients. Kidney and Dialysis, 2022, 2, 6-15.	1.0	0
9	A 30th anniversary and a glimpse of the future. Blood Pressure, 2022, 31, 1-3.	1.5	O
10	Twenty-Four Hour Blood Pressure Response to Empagliflozin and Its Determinants in Normotensive Non-diabetic Subjects. Frontiers in Cardiovascular Medicine, 2022, 9, 854230.	2.4	8
11	Defining intradialytic hypertension: the importance of measuring blood pressure accurately. Nephrology Dialysis Transplantation, 2022, 37, 1783-1785.	0.7	2
12	New Aspects in the Management of Hypertension in Patients with Chronic Kidney Disease not on Renal Replacement Therapy. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 125-135.	2.2	2
13	Hypertension management during the COVID-19 pandemic: what can we learn for the future?. Blood Pressure, 2022, 31, 47-49.	1.5	3
14	Empagliflozin Changes Urine Supersaturation by Decreasing pH and Increasing Citrate. Journal of the American Society of Nephrology: JASN, 2022, 33, 1073-1075.	6.1	8
15	High blood pressure screening in pharmacies during May Measurement Month campaigns in Switzerland. Blood Pressure, 2022, 31, 129-138.	1.5	1
16	Thirty years with LIFEâ€"a randomized clinical trial with more than 200 published articles on clinical aspects of left ventricular hypertrophy. Blood Pressure, 2022, 31, 125-128.	1.5	0
17	Sodium intake and progression of chronic kidney diseaseâ€"has the time finally come to do the impossible: a prospective randomized controlled trial?. Nephrology Dialysis Transplantation, 2021, 36, 381-384.	0.7	10
18	Effects of the Dual Endothelin Receptor Antagonist Aprocitentan on Body Weight and Fluid Homeostasis in Healthy Subjects on a High Sodium Diet. Clinical Pharmacology and Therapeutics, 2021, 109, 746-753.	4.7	14

#	Article	IF	CITATIONS
19	Blood pressure target in patients with hypertension and type-2 diabetes older than 65 years. Is <130/80 mmHg the right target or an excessive objective preventing from achieving the clinical goals we are aiming at?. Blood Pressure, 2021, 30, 79-81.	1.5	О
20	Uromodulin, Salt, and 24-Hour Blood Pressure in the General Population. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 787-789.	4.5	11
21	Dietary sodium intake does not alter renal potassium handling and blood pressure in healthy young males. Nephrology Dialysis Transplantation, 2021, , .	0.7	3
22	How Do I Manage Hypertension in Patients with Advanced Chronic Kidney Disease Not on Dialysis? Perspectives from Clinical Practice. Vascular Health and Risk Management, 2021, Volume 17, 1-11.	2.3	10
23	Editorial: Hypertension in the Elderly. Frontiers in Cardiovascular Medicine, 2021, 8, 645580.	2.4	2
24	Interprofessional Medication Adherence Program for Patients With Diabetic Kidney Disease: Protocol for a Randomized Controlled and Qualitative Study (PANDIA-IRIS). JMIR Research Protocols, 2021, 10, e25966.	1.0	5
25	Blood pressure monitoring in kidney transplantation: a systematic review on hypertension and target organ damage. Nephrology Dialysis Transplantation, 2021, 36, 1326-1346.	0.7	18
26	Better drug adherence improves blood pressure control and lowers cardiovascular disease outcomes $\hat{a} \in \text{``from single pill combinations to monitoring of a nationwide health insurance database.}$ Blood Pressure, 2021, 30, 1-2.	1.5	0
27	Sex differences in the progression of kidney injury and risk of death in CKD patients: is different ambulatory blood pressure control the underlying cause?. Nephrology Dialysis Transplantation, 2021, 36, 1965-1967.	0.7	1
28	Hypertension in kidney transplantation: a consensus statement of the †hypertension and the kidney†working group of the European Society of Hypertension. Journal of Hypertension, 2021, 39, 1513-1521.	0.5	16
29	Reply to comment on: Glatz et al. Associations of sodium, potassium and protein intake with blood pressure and hypertension in Switzerland. Swiss Medical Weekly, 2021, 151, w20182.	1.6	0
30	Smartphone based blood pressure measurement: accuracy of the OptiBP mobile application according to the AAMI/ESH/ISO universal validation protocol. Blood Pressure Monitoring, 2021, 26, 441-448.	0.8	25
31	Home blood pressure monitoring: methodology, clinical relevance and practical application: a 2021 position paper by the Working Group on Blood Pressure Monitoring and Cardiovascular Variability of the European Society of Hypertension. Journal of Hypertension, 2021, 39, 1742-1767.	0.5	82
32	Sodium-glucose cotransporter 2 (SGLT-2) inhibition and kidney protection: Does improvement in kidney hypoxia play a role?. EClinicalMedicine, 2021, 37, 100983.	7.1	1
33	Sex- and age-specific reference intervals for diagnostic ratios reflecting relative activity of steroidogenic enzymes and pathways in adults. PLoS ONE, 2021, 16, e0253975.	2.5	2
34	Assessment of a strategy combining ambulatory blood pressure, adherence monitoring and a standardised triple therapy in resistant hypertension. Blood Pressure, 2021, 30, 332-340.	1.5	1
35	Cuff-less measurements of blood pressure: are we ready for a change?. Blood Pressure, 2021, 30, 205-207.	1.5	7
36	Hypertension healthcare professional beliefs and behaviour regarding patient medication adherence: a survey conducted among European Society of Hypertension Centres of Excellence. Blood Pressure, 2021, 30, 282-290.	1.5	13

#	Article	IF	Citations
37	Clinical benefits of hypertension management: a look to the past to strengthen the future. European Journal of Preventive Cardiology, 2021, , .	1.8	1
38	Renal denervation for patients with chronic kidney disease and resistant hypertension: effective and safe but still not the panacea. Nephrology Dialysis Transplantation, 2021, , .	0.7	2
39	Missing Verification of Source Data in Hypertension Research: The HYGIA PROJECT in Perspective. Hypertension, 2021, 78, 555-558.	2.7	28
40	Hip Position Acutely Affects Oxygenation and Perfusion of Kidney Grafts as Measured by Functional Magnetic Resonance Imaging Methods—The Bent Knee Study. Frontiers in Medicine, 2021, 8, 697055.	2.6	4
41	Combining proteomics, home blood pressure telemonitoring and patient empowerment to improve cardiovascular and renal protection. Blood Pressure, 2021, 30, 267-268.	1.5	0
42	Global warming applied to dialysis: facts and figures. Nephrology Dialysis Transplantation, 2021, 36, 2167-2169.	0.7	7
43	Potential protective effects of antihypertensive treatments during the Covid-19 pandemic: from inhibitors of the renin-angiotensin system to beta-adrenergic receptor blockers. Blood Pressure, 2021, 30, 1-3.	1.5	16
44	Team-Based Care for Improving Hypertension Management: A Pragmatic Randomized Controlled Trial. Frontiers in Cardiovascular Medicine, 2021, 8, 760662.	2.4	6
45	Changes of lipoprotein(a) levels with endogenous steroid hormones. European Journal of Clinical Investigation, 2021, , e13699.	3.4	1
46	The five RADIANCE-HTN and SPYRAL-HTN randomised studies suggest that the BP lowering effect of RDN corresponds to the effect of one antihypertensive drug. Blood Pressure, 2021, 30, 327-331.	1.5	4
47	The unsolved challenge of implementing sustained reductions of sodium intake in patients with chronic kidney disease. Nephrology Dialysis Transplantation, 2021, 36, 1148-1151.	0.7	0
48	How reliable is renal ultrasound to measure renal length and volume in patients with chronic kidney disease compared with magnetic resonance imaging?. Acta Radiologica, 2020, 61, 117-127.	1.1	9
49	Comparative effectiveness of different antihypertensive agents in kidney transplantation: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 2020, 35, 878-887.	0.7	32
50	Renal handling of zinc in chronic kidney disease patients and the role of circulating zinc levels in renal function decline. Nephrology Dialysis Transplantation, 2020, 35, 1163-1170.	0.7	40
51	The Health Outcomes Prevention and Evaluation 4 (HOPE 4) project: A successful community-based intervention to lower cardiovascular risk in people with hypertension. Blood Pressure, 2020, 29, 1-2.	1.5	0
52	Impact of kidney transplantation on sleep apnea severity: A prospective polysomnographic study. American Journal of Transplantation, 2020, 20, 1659-1667.	4.7	7
53	Parathyroid Hormone and Plasma Phosphate Are Predictors of Soluble $\hat{l}_{\pm}$ -Klotho Levels in Adults of European Descent. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1135-e1143.	3.6	8
54	Sodium Intake Is Associated With Renal Resistive Index in an Adult Population-Based Study. Hypertension, 2020, 76, 1898-1905.	2.7	4

#	Article	IF	CITATIONS
55	Clinical Profiles and Factors Associated with a Low Sodium Intake in the Population: An Analysis of the Swiss Survey on Salt. Nutrients, 2020, 12, 3591.	4.1	3
56	Reference values and sex differences in absolute and relative kidney size. A Swiss autopsy study. BMC Nephrology, 2020, 21, 289.	1.8	18
57	Renal Functional Reserve Is Related to the Nondipping Phenotype and to the Exercise Heart Rate Response in Patients with Essential Hypertension and Preserved Renal Function. Kidney and Blood Pressure Research, 2020, 45, 737-747.	2.0	0
58	Management of Hyperuricemia in Patients with Chronic Kidney Disease: a Focus on Renal Protection. Current Hypertension Reports, 2020, 22, 102.	3.5	46
59	Blood pressure measurements with the OptiBP smartphone app validated against reference auscultatory measurements. Scientific Reports, 2020, 10, 17827.	3.3	41
60	The International Society of Hypertension Guidelines 2020 – a new drug treatment recommendation in the wrong direction?. Blood Pressure, 2020, 29, 264-266.	1.5	2
61	Water-Soluble Vitamin Levels and Supplementation in Chronic Online Hemodiafiltration Patients. Kidney International Reports, 2020, 5, 2160-2167.	0.8	11
62	Was it optimal to drop a diuretic as a first-line choice of drug treatment in the 2020 International Society of Hypertension Guidelines?. Blood Pressure, 2020, 29, 341-343.	1.5	2
63	Increasing potassium intake to prevent kidney damage: a new population strategy?. Kidney International, 2020, 98, 59-61.	5.2	4
64	Intensive systolic blood pressure control and prevention of new onset atrial fibrillation in the SPRINT study: is the association really controversial?. Blood Pressure, 2020, 29, 199-201.	1.5	0
65	Circadian variations in blood pressure and their implications for the administration of antihypertensive drugs: is dosing in the evening better than in the morning?. Journal of Hypertension, 2020, 38, 1396-1406.	0.5	23
66	Renin-Angiotensin System Blockade in Advanced Kidney Disease: Stop or Continue?. Kidney Medicine, 2020, 2, 231-234.	2.0	17
67	How to deal with the occurrence of rare drug-induced adverse events: the example of sprue-like enteropathy induced by olmesartan medoxomil and other angiotensin-receptor blockers. Blood Pressure, 2020, 29, 68-69.	1.5	0
68	Blood pressure medication should not be routinely dosed at bedtime. We must disregard the data from the HYGIA project. Blood Pressure, 2020, 29, 135-136.	1.5	31
69	Nutraceuticals and blood pressure control: a European Society of Hypertension position document. Journal of Hypertension, 2020, 38, 799-812.	0.5	43
70	Hypertension and Drug Adherence in the Elderly. Frontiers in Cardiovascular Medicine, 2020, 7, 49.	2.4	41
71	First Line CombinAtion Therapy in the Treatment of Stage II and III Hypertension (FLASH). Frontiers in Cardiovascular Medicine, 2020, 7, 46.	2.4	3
72	Hypertension, the renin–angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovascular Research, 2020, 116, 1688-1699.	3.8	282

#	Article	IF	Citations
73	Ambulatory Blood Pressure in Relation to Plasma and Urinary Manganese. Hypertension, 2020, 75, 1133-1139.	2.7	8
74	Inhibition of vascular calcification by inositol phosphates derivatized with ethylene glycol oligomers. Nature Communications, 2020, 11, 721.	12.8	38
75	Blood pressure medication should not be routinely dosed at bedtime. We must disregard the data from the HYGIA project. Journal of Hypertension, 2020, Publish Ahead of Print, .	0.5	2
76	Disregard the reported data from the HYGIA project: blood pressure medication not to be routinely dosed at bedtime. Journal of Hypertension, 2020, 38, 2144-2145.	0.5	14
77	Uranium exposure of the Swiss population based on 24-hour urinary excretion. Swiss Medical Weekly, 2020, 150, w20207.	1.6	2
78	OUP accepted manuscript. Nephrology Dialysis Transplantation, 2020, , .	0.7	1
79	Effect of angiotensin receptor blockers on blood pressure and renal function in patients with concomitant hypertension and chronic kidney disease: a systematic review and meta-analysis. Blood Pressure, 2019, 28, 358-374.	1.5	12
80	Exploring a new method for quantitative sodium MRI in the human upper leg with a surface coil and symmetrically arranged reference phantoms. Quantitative Imaging in Medicine and Surgery, 2019, 9, 985-999.	2.0	3
81	Sex and Body Mass Index Modify the Association Between Leptin and Sodium Excretion: A Cross-sectional Study in an African Population. American Journal of Hypertension, 2019, 32, 1101-1108.	2.0	2
82	Treatment of hypertension in the elderly in 2017/2018 - what $\hat{a} \in \mathbb{N}$ new?. Expert Opinion on Pharmacotherapy, 2019, 20, 1869-1877.	1.8	4
83	Systolic blood pressure control prevents cognitive decline and slows development of white matter lesions in the brain: the SPRINT MIND study outcomes. Blood Pressure, 2019, 28, 356-357.	1.5	5
84	New Insights on the Role of Sodium in the Physiological Regulation of Blood Pressure and Development of Hypertension. Frontiers in Cardiovascular Medicine, 2019, 6, 136.	2.4	15
85	FP760COMPARATIVE EFFECTIVENESS OF DIFFERENT ANTIHYPERTENSIVE AGENTS IN KIDNEY TRANSPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
86	Renal Resistive Index Is Associated With Inactive Matrix Gla (γ arboxyglutamate) Protein in an Adult Populationâ€Based Study. Journal of the American Heart Association, 2019, 8, e013558.	3.7	5
87	The PARAGON-Heart failure trial – another disappointment for heart failure patients with hypertension and preserved ejection fraction. Blood Pressure, 2019, 28, 276-278.	1.5	0
88	New data on antihypertensive drugs and risk of cancer: should we worry?. Blood Pressure, 2019, 28, 1-3.	1.5	9
89	Improving Blood Pressure Control in the Hypertensive Population. Hypertension, 2019, 74, 29-31.	2.7	5
90	Need for multiple risk reduction strategies in clinical trials enrolling high risk patients - FOURIER investigating PCSK-9 inhibitor to lower cholesterol revisited. Blood Pressure, 2019, 28, 144-145.	1.5	0

#	Article	IF	CITATIONS
91	The PARAGON Heart Failure trial $\hat{a}\in$ " ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction. Blood Pressure, 2019, 28, 215-216.	1.5	3
92	Urinary Sex Steroid and Glucocorticoid Hormones Are Associated With Muscle Mass and Strength in Healthy Adults. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2195-2215.	3.6	14
93	Acute hyperglycemia increases renal tissue oxygenation as measured by BOLD-MRI in healthy overweight volunteers. Diabetes Research and Clinical Practice, 2019, 150, 138-143.	2.8	14
94	Cardiovascular disease and uric acid: is the not-so-innocent bystander becoming a true culprit and does the US black box warning for febuxostat indicate that not all uric acid lowering is beneficial?. European Heart Journal, 2019, 40, 1787-1789.	2.2	15
95	Adherence in Hypertension. Circulation Research, 2019, 124, 1124-1140.	4.5	401
96	Reference intervals for the urinary steroid metabolome: The impact of sex, age, day and night time on human adult steroidogenesis. PLoS ONE, 2019, 14, e0214549.	2.5	38
97	Will we ever use angiotensin receptor neprilysin inhibition (ARNi) for the treatment of hypertension?. Blood Pressure, 2019, 28, 75-76.	1.5	5
98	Commentary: Statistical Adhockeries Are No Criteria for Legal Decisionsâ€"The Case of the Expert Medical Report on the Assessment of Urine Specimens Collected Among Athletes Having Participated to the Vancouver and Sochi Winter Olympic Games. Frontiers in Sociology, 2019, 4, 85.	2.0	0
99	Redefining diuretics use in hypertension. Journal of Hypertension, 2019, 37, 1574-1586.	0.5	72
100	Estimated 24-h urinary sodium and sodium-to-potassium ratio are predictors of kidney function decline in a population-based study. Journal of Hypertension, 2019, 37, 1853-1860.	0.5	22
101	Sodium intake and blood pressure in children with clinical conditions: A systematic review with metaâ€analysis. Journal of Clinical Hypertension, 2019, 21, 118-126.	2.0	22
102	Should we eat more potassium to better control blood pressure in hypertension?. Nephrology Dialysis Transplantation, 2019, 34, 184-193.	0.7	34
103	Controversies in the management of patients with arterial hypertension. Kardiologia Polska, 2019, 77, 902-907.	0.6	7
104	Urinary Cadmium Excretion Is Associated With Increased Synthesis of Cortico- and Sex Steroids in a Population Study. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 748-758.	3.6	18
105	Impact of salt reduction in meals consumed during hemodialysis sessions on interdialytic weight gain and hemodynamic stability. Hemodialysis International, 2018, 22, 501-506.	0.9	8
106	New 2017 American Heart Association and American College of Cardiology guideline for hypertension in the adults: major paradigm shifts, but will they help to fight against the hypertension disease burden?. Blood Pressure, 2018, 27, 62-65.	1.5	16
107	Reduced cortical oxygenation predicts a progressive decline of renal function in patients with chronic kidney disease. Kidney International, 2018, 93, 932-940.	5.2	133
108	Associations of Urinary Caffeine and Caffeine Metabolites With Arterial Stiffness in a Large Population-Based Study. Mayo Clinic Proceedings, 2018, 93, 586-596.	3.0	17

#	Article	IF	Citations
109	Blood pressure response to renal denervation is correlated with baseline blood pressure variability. Journal of Hypertension, 2018, 36, 221-229.	0.5	20
110	Should renal color Doppler ultrasonography be a routine test in newly diagnosed hypertensive patient?. Journal of Hypertension, 2018, 36, 16-22.	0.5	5
111	Challenges in oscillometric blood pressure measurement in atrial fibrillation: looking for practical solutions. Blood Pressure, 2018, 27, 1-2.	1.5	6
112	Prevalence of Hypertensive Phenotypes After Preeclampsia. Hypertension, 2018, 71, 103-109.	2.7	55
113	FO001SODIUM AND CHLORIDE CONCENTRATION OF SWEAT CORRELATE WITH DIETARY SALT INTAKE IN HEALTHY SUBJECTS. Nephrology Dialysis Transplantation, 2018, 33, i1-i1.	0.7	0
114	FP345ESTIMATED 24H URINARY SODIUM AND SODIUM TO POTASSIUM RATIO ARE PREDICTORS OF KIDNEY FUNCTION DECLINE IN A POPULATION BASED STUDY. Nephrology Dialysis Transplantation, 2018, 33, i147-i148.	0.7	0
115	2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Journal of Hypertension, 2018, 36, 2284-2309.	0.5	689
116	2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension. Blood Pressure, 2018, 27, 313-313.	1.5	14
117	2018 Practice guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Blood Pressure, 2018, 27, 314-340.	1.5	254
118	2018 ESC/ESH Guidelines for the management of arterial hypertension. Journal of Hypertension, 2018, 36, 1953-2041.	0.5	2,129
119	Intensive blood pressure lowering prevents mild cognitive impairment and possible dementia and slows development of white matter lesions in brain: the SPRINT Memory and Cognition IN Decreased Hypertension (SPRINT MIND) study. Blood Pressure, 2018, 27, 247-248.	1.5	47
120	Take a Blood Pressure Pill or Benefit from Renal Denervation?. European Heart Journal, 2018, 39, 3010-3012.	2.2	2
121	Ambulatory arterial stiffness index and blood pressure response to renal denervation. Journal of Hypertension, 2018, 36, 1272-1275.	0.5	2
122	Update on Endothelin Receptor Antagonists in Hypertension. Current Hypertension Reports, 2018, 20, 51.	3.5	17
123	Effects of the SGLT-2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-Diabetic Subjects: A Randomized, Double-Blind, Placebo-Controlled Study Protocol. Advances in Therapy, 2018, 35, 875-885.	2.9	11
124	Renal denervation achieved by endovascular delivery of ultrasound in RADIANCE-HTN SOLO or by radiofrequency energy in SPYRAL HTN-OFF and SPYRAL-ON lowers blood pressure. Blood Pressure, 2018, 27, 185-187.	1.5	5
125	Effect of Home Blood Pressure Monitoring on Patient's Awareness and Goal Attainment Under Antihypertensive Therapy: The Factors Influencing Results in Anti-HypertenSive Treatment (FIRST) Study. Kidney and Blood Pressure Research, 2018, 43, 979-986.	2.0	8
126	FO044UROMODULIN REFLECTS NEPHRON MASS IN THE GENERAL POPULATION AND KIDNEY DONORS. Nephrology Dialysis Transplantation, 2018, 33, i36-i36.	0.7	0

#	Article	IF	CITATIONS
127	Blood Pressure and Renal Responses to Orthostatic Stress Before and After Radiofrequency Renal Denervation in Patients with Resistant Hypertension. Frontiers in Cardiovascular Medicine, 2018, 5, 42.	2.4	6
128	Final Farewell to Alberto Zanchetti MD. European Heart Journal, 2018, 39, 2616-2617.	2.2	0
129	2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 2018, 39, 3021-3104.	2.2	6,826
130	Functional magnetic resonance imaging of the kidneys: where do we stand? The perspective of the European COST Action PARENCHIMA. Nephrology Dialysis Transplantation, 2018, 33, ii1-ii3.	0.7	32
131	Renal blood oxygenation level-dependent magnetic resonance imaging to measure renal tissue oxygenation: a statement paper and systematic review. Nephrology Dialysis Transplantation, 2018, 33, ii22-ii28.	0.7	88
132	Is There a Threshold for Medication Adherence? Lessons Learnt From Electronic Monitoring of Drug Adherence. Frontiers in Pharmacology, 2018, 9, 1540.	3.5	49
133	Epidemiological and histological findings implicate matrix Gla protein in diastolic left ventricular dysfunction. PLoS ONE, 2018, 13, e0193967.	2.5	10
134	Reduction of cortical oxygenation in chronic kidney disease: evidence obtained with a new analysis method of blood oxygenation level-dependent magnetic resonance imaging. Nephrology Dialysis Transplantation, 2017, 32, gfw362.	0.7	53
135	The INTERSALT Study and the complex relationship between salt intake and blood pressure. Blood Pressure, 2017, 26, 65-66.	1.5	2
136	Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure. Cancer Chemotherapy and Pharmacology, 2017, 79, 215-218.	2.3	2
137	The INTERSTROKE Study: hypertension is by far the most important modifiable risk factor for stroke. Blood Pressure, 2017, 26, 131-132.	1.5	9
138	Team-based care for improving hypertension management among outpatients (TBC-HTA): study protocol for a pragmatic randomized controlled trial. BMC Cardiovascular Disorders, 2017, 17, 39.	1.7	17
139	Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)*. Nephrology Dialysis Transplantation, 2017, 32, 620-640.	0.7	133
140	Is there a place for a dual angiotensin receptor-neprilysin inhibitor in the treatment of hypertension?. Journal of Hypertension, 2017, 35, 726-728.	0.5	0
141	Prevention of heart failure mortality and hospitalizations in SPRINT, EMPA-REG, ALLHAT and HYVET: are diuretics the clue?. Blood Pressure, 2017, 26, 193-194.	1.5	4
142	The Global Burden of Disease Study 2015 and Blood Pressure. Blood Pressure, 2017, 26, 1-1.	1.5	14
143	Renal denervation in hypertension: is it the end or the beginning of a SPYRAL?. Blood Pressure, 2017, 26, 319-320.	1.5	2
144	A population-based approach to assess the heritability and distribution of renal handling of electrolytes. Kidney International, 2017, 92, 1536-1543.	5.2	20

#	Article	IF	CITATIONS
145	Seasonality of sodium and potassium consumption in Switzerland. Data from three cross-sectional, population-based studies. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 792-798.	2.6	8
146	Treatment strategies for comorbid conditions lower residual risk in patients with treated hypertension: FOURIER and other randomized outcome trials. Blood Pressure, 2017, 26, 257-258.	1.5	2
147	Safety and Tolerability Study of an Intravenously Administered Small Interfering Ribonucleic Acid (siRNA) Post On-Pump Cardiothoracic Surgery in Patients at Risk of Acute Kidney Injury. Kidney International Reports, 2017, 2, 836-843.	0.8	31
148	Expertise: No Longer a Sine Qua Non for Guideline Authors?. Hypertension, 2017, 70, 235-237.	2.7	4
149	Performance of targeted screening for the identification of hypertension in children. Blood Pressure, 2017, 26, 87-93.	1.5	9
150	Optimizing hypertension management in renal transplantation: a call to action. Nephrology Dialysis Transplantation, 2017, 32, 1959-1962.	0.7	14
151	MP120THE URINARY UROMODULLIN CREATININE RATIO IS DECREASED 6 WEEKS POST-PARTUM IN WOMEN WITH PREECLAMPSIA. Nephrology Dialysis Transplantation, 2017, 32, iii472-iii472.	0.7	0
152	Comparative Long-Term Effect of Three Anti-P2Y12 Drugs after Percutaneous Angioplasty: An Observational Study Based on Electronic Drug Adherence Monitoring. Frontiers in Pharmacology, 2017, 8, 738.	3.5	2
153	Blood Oxygenation Level-Dependent MRI to Assess Renal Oxygenation in Renal Diseases: Progresses and Challenges. Frontiers in Physiology, 2017, 7, 667.	2.8	47
154	Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D). Therapeutics and Clinical Risk Management, 2017, Volume 13, 1569-1576.	2.0	4
155	Associations of sodium, potassium and protein intake with blood pressure and hypertension in Switzerland. Swiss Medical Weekly, 2017, 147, w14411.	1.6	18
156	Changing trends in end-stage renal disease patients with diabetes. Swiss Medical Weekly, 2017, 147, $\pm$ w14458.	1.6	13
157	Glycaemic, blood pressure and lipid goal attainment and chronic kidney disease stage of type 2 diabetic patients treated in primary care practices. Swiss Medical Weekly, 2017, 147, w14459.	1.6	7
158	MP641IMPACT OF REDUCING SALT CONTENT OF MEALS CONSUMED DURING HEMODIALYSIS SESSIONS ON HEMODYNAMIC STABILITY AND INTERDIALYTIC WEIGHT GAIN. Nephrology Dialysis Transplantation, 2016, 31, i554-i554.	0.7	0
159	Fibroblast growth factor 23 and markers of mineral metabolism in individuals with preserved renalÂfunction. Kidney International, 2016, 90, 648-657.	5.2	51
160	Relation of 24-hour urinary caffeine and caffeine metabolite excretions with self-reported consumption of coffee and other caffeinated beverages in the general population. Nutrition and Metabolism, 2016, 13, 81.	3.0	19
161	Effect of longâ€term adherence to clopidogrel on the VASPâ€PRI after elective coronary stent implantation: a randomized controlled study. British Journal of Clinical Pharmacology, 2016, 82, 1486-1497.	2.4	6
162	Blockade of the Reninâ€Angiotensin System and the Risk of Acute Kidney Injury. Journal of Clinical Hypertension, 2016, 18, 512-513.	2.0	4

#	Article	IF	CITATIONS
163	Resistant Hypertension. Hypertension, 2016, 68, 1346-1348.	2.7	1
164	Treatment of high blood pressure in elderly and octogenarians: European Society of Hypertension statement on blood pressure targets. Blood Pressure, 2016, 25, 333-336.	1.5	29
165	Renal tissue oxygenation in children with chronic kidney disease due to vesicoureteral reflux. Pediatric Nephrology, 2016, 31, 2103-2111.	1.7	5
166	Association between obesity and glomerular hyperfiltration: the confounding effect of smoking and sodium and protein intakes. European Journal of Nutrition, 2016, 55, 1089-1097.	3.9	45
167	Sociodemographic, behavioral and genetic determinants of allostatic load in a Swiss population-based study. Psychoneuroendocrinology, 2016, 67, 76-85.	2.7	50
168	CYP17A1 Enzyme Activity Is Linked to Ambulatory Blood Pressure in a Family-Based Population Study. American Journal of Hypertension, 2016, 29, 484-493.	2.0	13
169	Physiologic Control of the Circadian Variability in Blood Pressure. , 2016, , 149-163.		1
170	Chronic kidney disease in type 2 diabetic patients followed-up by primary care physicians in Switzerland: prevalence and prescription of antidiabetic drugs. Swiss Medical Weekly, 2016, 146, w14282.	1.6	8
171	Prevalence and determinants of chronic kidney disease in the Swiss population. Swiss Medical Weekly, 2016, 146, w14313.	1.6	11
172	Adherence to Medications in Uncontrolled Hypertension. Updates in Hypertension and Cardiovascular Protection, 2016, , 179-192.	0.1	0
173	Urinary angiotensinogen and salt sensitivity of blood pressure. Journal of Hypertension, 2015, 33, 1368-1370.	0.5	3
174	Drug adherence monitoring in clinical trials. Journal of Hypertension, 2015, 33, 2395-2398.	0.5	8
175	Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure. BioMed Research International, 2015, 2015, 1-9.	1.9	27
176	Prevalence and Diagnostic Approach to Sleep Apnea in Hemodialysis Patients: A Population Study. BioMed Research International, 2015, 2015, 1-9.	1.9	22
177	Prevalence of iodine inadequacy in Switzerland assessed by the estimated average requirement cut-point method in relation to the impact of iodized salt. Public Health Nutrition, 2015, 18, 1333-1342.	2.2	30
178	Drug adherence in chronic kidney diseases and dialysis. Nephrology Dialysis Transplantation, 2015, 30, 39-44.	0.7	93
179	A new technique with high reproducibility to estimate renal oxygenation using BOLD-MRI in chronic kidney disease. Magnetic Resonance Imaging, 2015, 33, 253-261.	1.8	40
180	New genetic loci link adipose and insulin biology to body fat distribution. Nature, 2015, 518, 187-196.	27.8	1,328

#	Article	IF	Citations
181	Associations of Ambulatory Blood Pressure With Urinary Caffeine and Caffeine Metabolite Excretions. Hypertension, 2015, 65, 691-696.	2.7	36
182	Pharmacokinetic modelling of dialytic clearance in a case of acyclovir intoxication. International Journal of Antimicrobial Agents, 2015, 45, 325-327.	2.5	2
183	What Is the Hypertension "Phenotype�. Current Cardiovascular Risk Reports, 2015, 9, 1.	2.0	4
184	Furosemide stimulation of parathormone in humans: role of the calcium-sensing receptor and the renin-angiotensin system. Pflugers Archiv European Journal of Physiology, 2015, 467, 2413-2421.	2.8	10
185	New anthropometry-based age- and sex-specific reference values for urinary 24-hour creatinine excretion based on the adult Swiss population. BMC Medicine, 2015, 13, 40.	5.5	57
186	A prospective observational study comparing a non-operator dependent automatic PWV analyser to pulse pressure, in assessing arterial stiffness in hemodialysis. BMC Nephrology, 2015, 16, 62.	1.8	9
187	Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis. Clinical Research in Cardiology, 2015, 104, 1097-1105.	3.3	76
188	ENaC activity in collecting ducts modulates NCC in cirrhotic mice. Pflugers Archiv European Journal of Physiology, 2015, 467, 2529-2539.	2.8	3
189	Obstructive Sleep Apnea Severity and Overnight Body Fluid Shift before and after Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1002-1010.	4.5	47
190	Inactive Matrix Gla-Protein Is Associated With Arterial Stiffness in an Adult Population–Based Study. Hypertension, 2015, 66, 85-92.	2.7	85
191	Copeptin Is Associated with Kidney Length, Renal Function, and Prevalence of Simple Cysts in a Population-Based Study. Journal of the American Society of Nephrology: JASN, 2015, 26, 1415-1425.	6.1	48
192	Modulation of Genetic Associations with Serum Urate Levels by Body-Mass-Index in Humans. PLoS ONE, 2015, 10, e0119752.	2.5	64
193	Epidemiology of Masked and White-Coat Hypertension: The Family-Based SKIPOGH Study. PLoS ONE, 2014, 9, e92522.	2.5	56
194	Determinants of Renal Tissue Oxygenation as Measured with BOLD-MRI in Chronic Kidney Disease and Hypertension in Humans. PLoS ONE, 2014, 9, e95895.	2.5	77
195	Eligibility for Renal Denervation. Hypertension, 2014, 63, 1319-1325.	2.7	61
196	Blood Pressure and Physical Activity: Time to Move (On). American Journal of Hypertension, 2014, 27, 1125-1125.	2.0	0
197	Ambulatory Blood Pressure and Adherence Monitoring: Diagnosing Pseudoresistant Hypertension. Seminars in Nephrology, 2014, 34, 498-505.	1.6	15
198	Reference Values and Factors Associated With Renal Resistive Index in a Family-Based Population Study. Hypertension, 2014, 63, 136-142.	2.7	97

#	Article	IF	CITATIONS
199	Managing â€~resistance'. Current Opinion in Nephrology and Hypertension, 2014, 23, 439-443.	2.0	24
200	Improving Blood Pressure Control Through Pharmacist Interventions: A Metaâ€Analysis of Randomized Controlled Trials. Journal of the American Heart Association, 2014, 3, e000718.	3.7	253
201	Response to Maximizing Treatment Adherence: Physician–Patient Partnerships vs Procedures. Hypertension, 2014, 63, e8.	2.7	0
202	State-of-the-art treatment of hypertension: established and new drugs. European Heart Journal, 2014, 35, 557-562.	2.2	30
203	Comparisons of Serum Vitamin D Levels, Status, and Determinants in Populations With and Without Chronic Kidney Disease Not Requiring Renal Dialysis: A 24-Hour Urine Collection Population-Based Study., 2014, 24, 303-312.		23
204	Should sodium intake be restricted in patients with CKD?. Nature Reviews Nephrology, 2014, 10, 363-364.	9.6	4
205	Pioglitazone Improves Fat Distribution, the Adipokine Profile and Hepatic Insulin Sensitivity in Non-Diabetic End-Stage Renal Disease Subjects on Maintenance Dialysis: A Randomized Cross-Over Pilot Study. PLoS ONE, 2014, 9, e109134.	2.5	13
206	Blockade of the Renin-Angiotensin System in Hypertensive Patients with Atherosclerotic Renal Artery Stenosis. Current Hypertension Reports, 2013, 15, 497-505.	3.5	0
207	Heritability, determinants and reference values of renal length: a family-based population study. European Radiology, 2013, 23, 2899-2905.	4.5	47
208	Discovery and refinement of loci associated with lipid levels. Nature Genetics, 2013, 45, 1274-1283.	21.4	2,641
209	Renal protection with calcium antagonists: the role of lercanidipine. Current Medical Research and Opinion, 2013, 29, 1727-1735.	1.9	16
210	Measuring, Analyzing, and Managing Drug Adherence in Resistant Hypertension. Hypertension, 2013, 62, 218-225.	2.7	189
211	2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal, 2013, 34, 2159-2219.	2.2	5,681
212	Renal Tissue Oxygenation in Essential Hypertension and Chronic Kidney Disease. International Journal of Hypertension, 2013, 2013, 1-7.	1.3	30
213	Step Count is Associated With Lower Nighttime Systolic Blood Pressure and Increased Dipping. American Journal of Hypertension, 2013, 26, 527-534.	2.0	18
214	Clinical Benefits of an Adherence Monitoring Program in the Management of Secondary Hyperparathyroidism with Cinacalcet: Results of a Prospective Randomized Controlled Study. BioMed Research International, 2013, 2013, 1-8.	1.9	23
215	Target blood pressure attainment with antihypertensive therapy in Swiss primary care. Blood Pressure, 2012, 21, 211-219.	1.5	9
216	Renal perfusion evaluation with contrast-enhanced ultrasonography. Nephrology Dialysis Transplantation, 2012, 27, 674-681.	0.7	73

#	Article	IF	CITATIONS
217	Short-Term Increase in Particulate Matter Blunts Nocturnal Blood Pressure Dipping and Daytime Urinary Sodium Excretion. Hypertension, 2012, 60, 1061-1069.	2.7	61
218	Blood pressure in hospitalized patients. Journal of Hypertension, 2012, 30, 1913-1914.	0.5	3
219	Endothelin receptor antagonists: a place in the management of essential hypertension?. Nephrology Dialysis Transplantation, 2012, 27, 865-868.	0.7	14
220	Pharmacokinetic evaluation of losartan. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 643-649.	3.3	24
221	Critical review of cancer risk associated with angiotensin receptor blocker therapy. Vascular Health and Risk Management, 2011, 7, 741.	2.3	11
222	Ambulatory Blood Pressure Monitoring to Assess Cardiovascular Risk in Women. Hypertension, 2011, 57, 377-378.	2.7	7
223	Lowering systolic blood pressure below 130 mm Hg does not improve cardiovascular outcomes in hypertensive patients with diabetes and coronary artery disease. Evidence-Based Medicine, 2011, 16, 24-26.	0.6	4
224	Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans. Journal of Hypertension, 2010, 28, 520-526.	0.5	12
225	Fixed combinations in the pragmatic management of hypertension: focus on aliskiren and hydrochlorothiazide as a single pill. Integrated Blood Pressure Control, 2010, 3, 57.	1.2	2
226	Effect of Sodium Loading/Depletion on Renal Oxygenation in Young Normotensive and Hypertensive Men. Hypertension, 2010, 55, 1116-1122.	2.7	69
227	Genome-Wide Association Study of Blood Pressure Extremes Identifies Variant near UMOD Associated with Hypertension. PLoS Genetics, 2010, 6, e1001177.	3.5	312
228	Glomerular hyperfiltration and increased proximal sodium reabsorption in subjects with type 2 diabetes or impaired fasting glucose in a population of the African region. Nephrology Dialysis Transplantation, 2010, 25, 2225-2231.	0.7	51
229	Less frequent dosing of erythropoiesis stimulating agents in patients undergoing dialysis: a European multicentre cost study. Journal of Medical Economics, 2009, 12, 77-86.	2.1	8
230	Aldosterone and cardiovascular risk. Current Hypertension Reports, 2009, 11, 450-455.	3.5	21
231	Association Between White-Coat Effect and Blunted Dipping of Nocturnal Blood Pressure. American Journal of Hypertension, 2009, 22, 1054-1061.	2.0	12
232	Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine?. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 981-987.	3.3	16
233	Ethnic differences in proximal and distal tubular sodium reabsorption are heritable in black and white populations. Journal of Hypertension, 2009, 27, 606-612.	0.5	54
234	Alterations of renal sodium handling in arterial hypertension. Current Hypertension Reports, 2008, 10, 85-86.	3.5	1

#	Article	IF	Citations
235	Impact of electronic monitoring of drug adherence on blood pressure control in primary care: A cluster 12-month randomised controlled study. European Journal of Internal Medicine, 2008, 19, 427-434.	2.2	61
236	Hemodynamic effect of angiotensin II receptor blockade in postmenopausal women on a high-sodium diet: A double-blind, randomized, placebo-controlled study. Current Therapeutic Research, 2008, 69, 467-479.	1.2	2
237	Endâ€digit preference in general practice: A comparison of the conventional auscultatory and electronic oscillometric methods. Blood Pressure, 2008, 17, 104-109.	1.5	24
238	Ethnic Differences in Renal Handling of Water and Solutes in Hypertension. Hypertension, 2008, 52, 203-204.	2.7	7
239	Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ: British Medical Journal, 2008, 336, 1114-1117.	2.3	684
240	Nighttime Blood Pressure and Nocturnal Dipping Are Associated With Daytime Urinary Sodium Excretion in African Subjects. Hypertension, 2008, 51, 891-898.	2.7	153
241	Relationships among endogenous ouabain, $\hat{l}_{\pm}$ -adducin polymorphisms and renal sodium handling in primary hypertension. Journal of Hypertension, 2008, 26, 914-920.	0.5	48
242	Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine. Vascular Health and Risk Management, 2008, Volume 4, 1159-1166.	2.3	14
243	High salt intake: a cause of blood pressure-independent left ventricular hypertrophy?. Nephrology Dialysis Transplantation, 2007, 22, 2426-2429.	0.7	30
244	CYP3A5 and ABCB1 Genes Influence Blood Pressure and Response to Treatment, and Their Effect Is Modified by Salt. Hypertension, 2007, 49, 1007-1014.	2.7	59
245	Improving Blood Pressure Control in the Community: Can New Technologies Help Us?. American Journal of Hypertension, 2007, 20, 949-949.	2.0	2
246	Hypertension and the Kidney: New Avenues for an Improved Management of Hypertension in Renal Diseases: Introduction. Seminars in Nephrology, 2007, 27, 509-510.	1.6	0
247	Renal Sodium Handling and Nighttime Blood Pressure. Seminars in Nephrology, 2007, 27, 565-571.	1.6	43
248	The Association of Aldosterone With Obesity-Related Hypertension and the Metabolic Syndrome. Seminars in Nephrology, 2007, 27, 529-537.	1.6	39
249	Efficacy and tolerability of lercanidipine in patients with hypertension: results of a Phase IV study in general practice. Expert Opinion on Pharmacotherapy, 2007, 8, 2215-2223.	1.8	17
250	Clinical evaluation of IDAS II, a new electronic device enabling drug adherence monitoring. European Journal of Clinical Pharmacology, 2007, 63, 1179-1184.	1.9	42
251	Medication Adherence and Persistence as the Cornerstone of Effective Antihypertensive Therapy. American Journal of Hypertension, 2006, 19, 1190-1196.	2.0	270
252	Association of CYP3A5 genotypes with blood pressure and renal function in African families. Journal of Hypertension, 2006, 24, 923-929.	0.5	44

#	Article	IF	CITATIONS
253	Proximal tubular function and salt sensitivity. Current Hypertension Reports, 2006, 8, 8-15.	3.5	26
254	Plasma Aldosterone Is Independently Associated With the Metabolic Syndrome. Hypertension, 2006, 48, 239-245.	2.7	204
255	Increased carotid intima–media thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease. Acta Paediatrica, International Journal of Paediatrics, 2006, 95, 63-68.	1.5	6
256	Heritability of renal function in hypertensive families of African descent in the Seychelles (Indian) Tj ETQq0 0 0 rg	gBT/Overlo	ock 10 Tf 50 (
257	Determinants of persistence in hypertensive patients treated with irbesartan: results of a postmarketing survey. BMC Cardiovascular Disorders, 2005, 5, 13.	1.7	23
258	The safety of rofecoxib. Expert Opinion on Drug Safety, 2005, 4, 491-499.	2.4	34
259	High Heritability of Ambulatory Blood Pressure in Families of East African Descent. Hypertension, 2005, 45, 445-450.	2.7	73
260	Female sex hormones, salt, and blood pressure regulation. American Journal of Hypertension, 2004, 17, 994-1001.	2.0	186
261	Angiotensin II Receptor Blockade. Hypertension, 2003, 41, 31-36.	2.7	94
262	Monitoring compliance in resistant hypertension: an important step in patient management. Journal of Hypertension, 2003, 21, S37-S42.	0.5	72
263	Blood Pressure, Cardiac, and Renal Responses to Salt and Deoxycorticosterone Acetate in Mice: Role of Renin Genes. Journal of the American Society of Nephrology: JASN, 2002, 13, 1509-1516.	6.1	70
264	Comparative angiotensin II receptor blockade in healthy volunteers: The importance of dosing. Clinical Pharmacology and Therapeutics, 2002, 71, 68-76.	4.7	84
265	Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. Journal of Hypertension, 2001, 19, 335-341.	0.5	236
266	Renal determinants of the salt sensitivity of blood pressure. Nephrology Dialysis Transplantation, 2001, 16, 452-458.	0.7	39
267	Angiotensin II Type 1 Receptor Blockers. Circulation, 2001, 103, 904-912.	1.6	451
268	Does protein binding modulate the effect of angiotensin II receptor antagonists?. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2001, 2, S54-S58.	1.7	7
269	Blood pressure and renal haemodynamic response to salt during the normal menstrual cycle. Clinical Science, 2000, 98, 697-702.	4.3	33
270	Renal sodium handling in acute and chronic salt loading/depletion protocols. Journal of Hypertension, 2000, 18, 1657-1664.	0.5	30

#	Article	IF	CITATIONS
271	Is nurse-measured blood pressure a valid substitute for ambulatory blood pressure monitoring?. Blood Pressure Monitoring, 2000, 5, 203-209.	0.8	10
272	Salt- And Angiotensin Ii-Dependent Variations In Amiloride-Sensitive Rectal Potential Difference In Mice. Clinical and Experimental Pharmacology and Physiology, 2000, 27, 60-66.	1.9	38
273	Proximal Sodium Reabsorption. Hypertension, 2000, 36, 631-637.	2.7	106
274	Why Objective Monitoring of Compliance is Important in the Management of Hypertension. Journal of Clinical Hypertension, 2000, 2, 258-262.	2.0	19
275	Angiotensin II Receptor Blockade in Normotensive Subjects. Hypertension, 1999, 33, 850-855.	2.7	102
276	Adducin Polymorphism Affects Renal Proximal Tubule Reabsorption in Hypertension. Hypertension, 1999, 33, 694-697.	2.7	118
277	Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clinical Pharmacology and Therapeutics, 1999, 66, 76-84.	4.7	286
278	Comparative Safety and Tolerability of Angiotensin II Receptor Antagonists. Drug Safety, 1999, 21, 23-33.	3.2	85
279	Electronic Monitoring of Compliance to Lipid-Lowering Therapy in Clinical Practice. Journal of Clinical Pharmacology, 1999, 39, 402-409.	2.0	72
280	Pharmacology of valsartan, an angiotensin II receptor antagonist. Expert Opinion on Investigational Drugs, 1998, 7, 1915-1925.	4.1	26
281	Sinistrin Clearance for Determination of Glomerular Filtration Rate: A Reappraisal of Various Approaches Using a New Analytical Method. Journal of Clinical Pharmacology, 1997, 37, 679-692.	2.0	33
282	Isolated office hypertension: a prehypertensive state? Journal of Hypertension, 1996, 14, 327-332.	0.5	117
283	Differential Nitric Oxide Synthase Activity in Human Platelets during Normal Pregnancy and Pre-Eclampsia. Clinical Science, 1995, 88, 607-610.	4.3	39
284	Angiotensin II Antagonists. Clinical and Experimental Hypertension, 1993, 15, 1221-1238.	1.3	9
285	Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteers. Clinical Pharmacology and Therapeutics, 1991, 50, 181-191.	4.7	24
286	Comparative Cardiovascular Effects of Drugs Used for Hypertension. Drugs, 1990, 39, 32-38.	10.9	7
287	The Place of Microelectronic Systems in Measuring Compliance. , 0, , 85-96.		2